Your Doctor Prescribed the Standard Dose, but Your Genes Didn't Get the Memo.

Your CYP2D6 gene encodes an enzyme in your liver that breaks down a massive class of medications. It’s responsible for metabolizing antidepressants like venlafaxine and fluoxetine, opioid painkillers like codeine and tramadol, beta-blockers for heart rate and blood pressure, and many anti-nausea medications. This single enzyme is the gatekeeper for roughly one-quarter of all prescription drugs.

CYP2D6 comes in many variants, and some people carry duplications of the entire gene. Poor metabolizers, roughly 7 to 10% of people with European ancestry, have non-functional copies or only one working copy. Ultra-rapid metabolizers carry duplications and metabolize drugs at 2 to 3 times the normal speed. If you’re a poor metabolizer taking an antidepressant at the standard dose, the drug accumulates in your bloodstream to levels that cause tremors, confusion, and emotional blunting, while you believe the medication simply isn’t working.

You experience side effects at standard doses that other people tolerate fine. Or you don’t experience any therapeutic benefit because you’re metabolizing the drug too quickly. Either way, you change medications repeatedly, never finding one that works, when the problem was never the drug itself, it was the dose relative to your genes.

CYP2C19 metabolizes several important medication classes, but it’s most famous for one critical job: converting the blood thinner clopidogrel (Plavix) into its active form. Clopidogrel is a prodrug, meaning it’s inactive until your liver converts it. If you have a CYP2C19 variant, your liver might not make this conversion efficiently.

Poor metabolizers, ranging from 2% to 15% depending on your ancestry, carry variants (*2 or *3) that severely reduce enzyme function. Ultra-rapid metabolizers carry the *17 variant and convert clopidogrel very quickly. If you’re a poor metabolizer taking clopidogrel after a stent placement or stroke, you receive zero antiplatelet benefit, and you’re at serious risk of a second event, while your doctor believes you’re fully protected.

Beyond clopidogrel, this gene also metabolizes certain proton pump inhibitors (acid reflux medications), some antidepressants, and antifungal drugs. If you’re a poor metabolizer on omeprazole and an antidepressant together, both drugs accumulate, and side effects multiply while you’re at the standard dose.

CYP2C9 metabolizes warfarin, the gold standard anticoagulant for atrial fibrillation and certain clotting disorders. It also metabolizes NSAIDs like ibuprofen and naproxen, plus some statins and diabetes medications. This is another gene where poor metabolism has immediate, serious consequences.

Poor metabolizers, roughly 5 to 10% of people with European ancestry, carry *2 or *3 variants that reduce enzyme activity by 50-90%. If you’re a poor metabolizer starting warfarin at a standard dose, the drug accumulates and you become dangerously over-anticoagulated, with elevated bleeding risk, sometimes within days.

You might notice unusual bruising, bleeding gums, or blood in your urine and don’t connect it to your blood thinner because you assumed you were on the correct dose. Your INR (International Normalized Ratio, the test for warfarin effectiveness) comes back alarmingly high, and your doctor assumes you took too much or changed your diet, when really your genes make you sensitive to the standard dose.

VKORC1 encodes the enzyme that recycles vitamin K in your body. Warfarin works by blocking this enzyme, preventing vitamin K recycling, which stops your liver from producing clotting factors. The more efficiently your VKORC1 enzyme works, the more warfarin you need to overcome it. The less efficiently it works, the more sensitive you are to warfarin.

The VKORC1 -1639G>A variant is common, found in roughly 40% of people with European ancestry and even more common in people of Asian or African ancestry. If you carry the A allele, your vitamin K recycling is already less efficient, meaning you need lower warfarin doses than the average patient.

This is one of the few genes where a single variant creates a major dosing difference. You start on the standard warfarin dose, your INR shoots high, you have bleeding symptoms, and your doctor assumes miscommunication or non-compliance, when really your genes made you significantly more sensitive to the drug than the standard protocol assumed.

SLCO1B1 encodes a transporter protein that actively pumps statins from your bloodstream into your liver cells, where they work. If this transporter doesn’t function well, statins accumulate in your bloodstream instead of entering liver cells. This puts you at elevated risk of statin-related muscle injury (myopathy), even at standard doses.

The rs4149056 variant creates a reduced-function transporter. The C allele occurs in roughly 15% of people with European ancestry. If you carry this variant and take simvastatin, atorvastatin, or lovastatin at a standard dose, the drug accumulates systemically and you’re at significantly higher risk of muscle pain, weakness, and rhabdomyolysis compared to people with normal transporter function.

You develop muscle aches and assume it’s aging or exercise-related. Your doctor checks your CK (creatine kinase, a muscle damage marker) and it’s elevated, so you stop the statin, convinced you’re intolerant to the entire drug class, when really the specific dose of that specific statin was too high for your genes.

MTHFR encodes methylenetetrahydrofolate reductase, a central enzyme in your methylation cycle and folate metabolism. This gene is relevant to medication response because many drugs depend on folate-dependent pathways for metabolism and because MTHFR variants affect your baseline methylation capacity, which influences how you respond to medications that depend on methylation.

The C677T variant is common, found in roughly 40% of people with European ancestry. Carriers have 30-65% reduced enzyme activity. If you carry the C677T variant and take methotrexate (used for rheumatoid arthritis, psoriasis, and cancer), you may experience more severe side effects and require lower doses because your reduced folate metabolism makes you more sensitive to the drug’s folate-depleting effects.

Beyond methotrexate, MTHFR variants affect your response to medications and supplements that depend on adequate methylation capacity. You might struggle with standard doses of antidepressants, experience worse side effects from statins, or not respond well to B-vitamin supplementation because your impaired conversion means supplementing with non-methylated forms is ineffective.